GRAPPA 2025
GRAPPA 2024
GRAPPA 2023
GRAPPA 2022
Psoriasis
Psoriatic Arthritis
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 hours ago
- Yahoo
This test can predict how long a middle-aged person will live in just a few seconds
When it comes to longevity, it's not just about living for as many years as possible. The goal is to live healthier, and free of disease or injury, for as long as possible. Healthy aging often boils down to simple habits like exercising regularly, eating a nutritious diet rich in fiber, getting enough sleep, and connecting with others. Even if a person practices these habits, is there a way to know how long they'll live? While there's no crystal ball for lifespan, there is a simple test you can take in middle age that may help predict how many years you have left. An exercise researcher reveals why this test can be a good indicator of longevity and a wakeup call to change your lifestyle. Longevity Tip of the Day: The Sitting-to-Rising Test May Predict How Long You'll Live The sitting-to-rising test (SRT) is a measure of how easy or difficult it is to sit on the floor without using the arms, hands or knees for support or balance, and stand back up again without assistance. The SRT assesses a person's non-aerobic physical fitness, which includes muscle strength, balance, flexibility, and a healthy body composition. These are also all indicators of healthy aging, Dr. Claudio Gil Araújo, a sports medicine physician and researcher at the Exercise Medicine Clinic in Rio de Janeiro, told NBC News. New research led by Araújo shows that a person's score on this test may predict how many years they have left to live, according to a report published in the European Journal of Preventive Cardiology. Araújo's team administered the SRT to 4,282 adults aged 46–75, using a 0-5 point system. A perfect score (five points) required going from a sitting to rising position unassisted. Any time a body part was used to balance or get up, one point was subtracted. The researchers followed up 12 years later and found that the vast majority of people with perfect scores were still alive, compared to less than half of those who scored four points or less. The authors concluded that the SRT was a strong predictor of natural and cardiovascular mortality. While the test doesn't directly prove that a perfect score results in a longer lifespan, 'it is quite reasonable to expect this,' Araújo told NBC News. Why It Matters 'Aerobic fitness is important, but muscle strength, a healthy body mass index, balance and flexibility are also vital for healthy aging,' Araújo said. The SRT is not perfect, but it is a reliable indicator of longevity because it assesses these factors. However, the real value of this test may be that it can serve as a warning sign to start changing your habits. Fortunately, the score you get on the test is not final. Instead, it can give a snapshot of your fitness level and what you need to improve upon — especially if you're in your 50s, which is an ideal time to start building healthy aging habits. If your SRT score is low, you can work on these deficits by building strength and balance to score higher, Araújo said. How to Get Started Always consult with your doctor before trying the test at home, especially if you have underlying health issues or injuries. In order to do the sitting-to-rising test, all you need is another person to keep score (you can use a 10-point system). Here's how: Start from a standing position. Slowly sit on the floor crosslegged without using any other body part to balance. Stand up from this position, without any assistance. Subtract one point every time you use your hand, knee, forearm, or side of your leg to help. If are able to sit down and stand back up with no assistance, you score a perfect 10. If you couldn't get off the ground, you score a zero. A good score would be considered eight or higher. TODAY's Expert Tip of the Day series is all about simple strategies to make life a little easier. Every Monday through Friday, different qualified experts share their best advice on diet, fitness, heart health, mental wellness and more. This article was originally published on
Yahoo
3 days ago
- Yahoo
Fla sack doctor José Luiz Runco after comments on De La Cruz
Flamengo has decided to fire José Luiz Runco. The head of the medical department leaves the Rio club one day after a message was released in which he said that Nico De la Cruz has a "chronic and irreparable injury". The information was first published by journalist Bruno Castanha and confirmed by Flamengo has not yet officially commented. Understand This Tuesday, Flamengo's general medical director, José Luiz Runco criticized the physical condition of Nico De La Cruz. According to information published by 'GE', Runco sent a message in a Whatsapp group, formed by several members of Fla's politics, criticizing the signing of Nicolás De La Cruz. "Dear João. Good afternoon. I will try to explain the situation of De la Cruz. Player bought in another administration, without the slightest condition, as he presents a chronic and irreparable injury in the right knee, and an injury also in the left knee. As we are bipeds, we have balance and muscle balance difficulties if any limb is already affected. We are trying to do our best so he can participate, but it is very complicated. And, about the sale, only if there is some club that is interested for another reason and not to play competitive football. Sincerely", said Runco. The player's staff publicly said that the doctor lacked ethics. The agents are still considering suing Runco. Earlier this Wednesday, Flamengo released a note stating the message was not written by a club professional. 'The Football Directorate of Clube de Regatas do Flamengo clarifies that the recently leaked message was not written by any of the five doctors who make up the professional football department: Fernando Sassaki (orthopedist and head of the sector), Luiz Macedo (cardiologist), Dieno Portella (orthopedist), Vitor Pereira (orthopedist) and Bruno Hassel (radiologist)', Flamengo wrote. This article was translated into English by Artificial Intelligence. You can read the original version in 🇧🇷 here. 📸 MAURO PIMENTEL - AFP or licensors
Yahoo
4 days ago
- Yahoo
AstraZeneca's Tagrisso combo shows OS improvement in Phase III NSCLC trial
AstraZeneca's Tagrisso (osimertinib) combined with pemetrexed and platinum-based chemotherapy has shown improvement in overall survival (OS) for those with first-line locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). According to the final analysis of the randomised Phase III trial, FLAURA2, it demonstrated a consistent survival benefit, echoing interim OS outcomes and building upon the earlier reported longest median progression-free survival (PFS) data for this setting. The combo showed OS improvements in the open-label, global, multi-centre trial when compared against Tagrisso as a single agent for this patient group. Subjects in the trial received 80mg of Tagrisso daily in oral tablet form, combined with a chemotherapy regimen. The chemotherapy included pemetrexed at a dosage of 500mg/m² and either cisplatin at 75mg/m² or carboplatin (AUC5) administered every three weeks for a total of four cycles. After completing the cycles, the treatment continued with Tagrisso alongside maintenance doses of pemetrexed, also given every three weeks. A total of 557 subjects were enrolled in the trial in more than 150 centres across over 20 nations, including in Asia, Europe, South America, and the US. PFS is the primary endpoint of the trial. The combination therapy's safety profile remained manageable, aligning with known profiles of the individual medicines. According to the company, the trial recorded higher adverse event rates in the combination arm, attributed to expected chemotherapy-related effects. Discontinuation rates due to adverse events remained low. These findings are set to be presented at an upcoming medical meeting and will be communicated to global regulatory bodies. AstraZeneca oncology haematology R&D executive vice-president Susan Galbraith said: 'These exciting overall survival results add to the extensive evidence supporting Tagrisso as the backbone therapy in EGFR-mutated lung cancer, demonstrating that Tagrisso plus chemotherapy can significantly extend survival in the first-line advanced setting, in addition to prior trials showing survival benefits as monotherapy in both early stage and advanced disease.' More than 80 nations, including the European Union (EU), the US, Japan, and China, have currently approved Tagrisso + chemotherapy based on the FLAURA2 trial data. In 2023, AstraZeneca reported positive outcomes from the ADAURA Phase III trial of Tagrisso in the adjuvant treatment of individuals with Stage IB, II, IIIA EGFRm NSCLC. "AstraZeneca's Tagrisso combo shows OS improvement in Phase III NSCLC trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
